BioSpace News Archive

Edgewise Therapeutics, Inc. announced today that management will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 13, 2023, at 10 am PT (1 pm ET).

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company’s Board of Directors.

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced the appointment of commercial veteran, Michael G. Vicari, as Chief Commercial Officer.

Medtech startup AVATAR MEDICAL announced today that its virtual reality (VR) surgical planning solution has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

GIE Medical was granted designation as a Breakthrough Device from the U.S. Food and Drug Administration (FDA) for its ProTractX3™ TTS DCB indicated for dilation of recurrent benign esophageal strictures in adults with obstructive symptoms associated with narrowing of the esophagus.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced acceptance for publication by Frontiers in Molecular Biosciences of a preclinical study using TransCode’s lead therapeutic candidate, TTX-MC138, in glioblastoma multiforme (GBM).

SomaLogic, Inc., a leader in proteomics technology, announced a Chief Financial Officer transition.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock.

Ionis Pharmaceuticals, Inc. announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Vivos Therapeutics, Inc. announced it plans to release its first quarter 2023 financial results after market close on Thursday, June 8, 2023.